secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0000950170-24-027951
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics reports FY2023 net loss $21.5M; cash runway into Q3 2025
--------------------------------------------------------------------------------

- FY2023 revenue $8.9M, down 39% from $14.7M in 2022; net loss $21.5M ($0.12/sh).
- Q4 2023 net loss $4.8M ($0.03/sh); total operating expenses $8.2M.
- Cash $35.5M at 12/31/23 plus $13.8M net from Feb 2024 offering; funds operations into Q3 2025.
- OpRegen Phase 2a for dry AMD ongoing with Roche/Genentech; OPC1 IND cleared for spinal cord trial.
- Initiated hypoimmune iPSC cell line for neurology under Eterna Therapeutics collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/0000950170-24-027951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017024027951/lctx-20240307.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-027951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer